Precision medicine for severe asthma – Biological targeted therapy

• Published in: International immunopharmacology 2024-06, Vol.134, p.112189, Article 112189
• Main Authors: Sun, Bingqing, Shen, Kunlu, Zhao, Ruiheng, Li, Yun, Xiang, Min, Lin, Jiangtao
• Format: Article
• Language: English
• Subjects: Biological agents; Biomarkers; Precision medicine; Severe asthma
• ISSN: 1567-5769; 1878-1705; 1878-1705
• DOI: 10.1016/j.intimp.2024.112189

•Severe asthma is a complex and heterogeneous chronic airway inflammatory disease.•Current treatment strategies are focused on the personalized medicine by integrating biomarkers and monoclonal antibodies.•This article provides a comprehensive review on biomarkers and biological agents for severe asthma. Severe asthma is a complex and heterogeneous chronic airway inflammatory disease. Current treatment strategies are increasingly focused on disease classification, facilitating the transition towards personalized medicine by integrating biomarkers and monoclonal antibodies for tailored therapeutic approaches. Several approved biological agents, including anti-immunoglobulin E (IgE), anti-interleukin (IL)-4, anti-IL-5, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have demonstrated significant efficacy in reducing asthma exacerbations, eosinophil counts, improving lung function, minimizing oral corticosteroid usage, and enhancing patients' quality of life. The utilization of these biological agents has brought about profound transformations in the management of severe asthma. This article provides a comprehensive review on biomarkers and biological agents for severe asthma while emphasizing the increasing importance of further research into its pathogenesis and novel treatment modalities.